ly-2157299 Search Results


ly2157299  (MedChemExpress)
95
MedChemExpress ly2157299
Ly2157299, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299/product/MedChemExpress
Average 95 stars, based on 1 article reviews
ly2157299 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
ly2157299 galunisertib  (TargetMol)
92
TargetMol ly2157299 galunisertib
Ly2157299 Galunisertib, supplied by TargetMol, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299 galunisertib/product/TargetMol
Average 92 stars, based on 1 article reviews
ly2157299 galunisertib - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier
tgfβri inhibitor25 26  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology tgfβri inhibitor25 26
Tgfβri Inhibitor25 26, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tgfβri inhibitor25 26/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
tgfβri inhibitor25 26 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
galunisertib ly2157299  (Eli Lilly)
90
Eli Lilly galunisertib ly2157299
Future Drugs for HCC.
Galunisertib Ly2157299, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galunisertib ly2157299/product/Eli Lilly
Average 90 stars, based on 1 article reviews
galunisertib ly2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly2157299 (tgfbri  (Eli Lilly)
90
Eli Lilly ly2157299 (tgfbri
Future Drugs for HCC.
Ly2157299 (Tgfbri, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299 (tgfbri/product/Eli Lilly
Average 90 stars, based on 1 article reviews
ly2157299 (tgfbri - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly2157299  (Axon Medchem LLC)
90
Axon Medchem LLC ly2157299
Future Drugs for HCC.
Ly2157299, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
ly2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly2157299  (Cayman Chemical)
90
Cayman Chemical ly2157299
Future Drugs for HCC.
Ly2157299, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
ly2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly-2157299  (PeproTech)
90
PeproTech ly-2157299
Future Drugs for HCC.
Ly 2157299, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly-2157299/product/PeproTech
Average 90 stars, based on 1 article reviews
ly-2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly2157299 nivolumab  (Bristol Myers)
90
Bristol Myers ly2157299 nivolumab
Different molecular targeted agents, and their combinations with other agents under clinical evaluation in HCC (as of December 2019) 1 .
Ly2157299 Nivolumab, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299 nivolumab/product/Bristol Myers
Average 90 stars, based on 1 article reviews
ly2157299 nivolumab - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
galunisertib (ly 2157299)  (Axon Medchem LLC)
90
Axon Medchem LLC galunisertib (ly 2157299)
Preparation and Characterization of the AuDNP-LY@Gel system. ( a ) Schematic representation of the functionalization procedure. The growth of AuNPs on the surface of the DNP is achieved by dispersing amino-modified DNPs in the HAuCl 4 solution and adding gelatin as a stabilizing agent. NaBH 4 is used as the reducing agent. Then, the small molecule <t>Galunisertib</t> is loaded into the system and the gelatin shell is performed by crosslinking of the polymer matrix. The scheme is not in scale and not intended to represent the full sample composition. ( b ) TEM investigations of the AuDNP (I), AuDNP-LY@Gel 0.125% (II) and AuDNP-LY@Gel 0.5% samples ( c ). Particle size analysis of AuNPs decorating the surface of the DNP fitted by a Gaussian curve. ( d ) Change in the size (black) and surface charge (blue) of the samples AuDNP-LY@Gel according to the different gelatin amounts in the outer shell. The vertical bars are representative of the standard deviation (SD) on a minimum of three independent measurements.
Galunisertib (Ly 2157299), supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galunisertib (ly 2157299)/product/Axon Medchem LLC
Average 90 stars, based on 1 article reviews
galunisertib (ly 2157299) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ly2157299  (Xcessbio Inc)
90
Xcessbio Inc ly2157299
Preparation and Characterization of the AuDNP-LY@Gel system. ( a ) Schematic representation of the functionalization procedure. The growth of AuNPs on the surface of the DNP is achieved by dispersing amino-modified DNPs in the HAuCl 4 solution and adding gelatin as a stabilizing agent. NaBH 4 is used as the reducing agent. Then, the small molecule <t>Galunisertib</t> is loaded into the system and the gelatin shell is performed by crosslinking of the polymer matrix. The scheme is not in scale and not intended to represent the full sample composition. ( b ) TEM investigations of the AuDNP (I), AuDNP-LY@Gel 0.125% (II) and AuDNP-LY@Gel 0.5% samples ( c ). Particle size analysis of AuNPs decorating the surface of the DNP fitted by a Gaussian curve. ( d ) Change in the size (black) and surface charge (blue) of the samples AuDNP-LY@Gel according to the different gelatin amounts in the outer shell. The vertical bars are representative of the standard deviation (SD) on a minimum of three independent measurements.
Ly2157299, supplied by Xcessbio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly2157299/product/Xcessbio Inc
Average 90 stars, based on 1 article reviews
ly2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
galunisertib (ly2157299  (Biozol Diagnostica Vertrieb GmbH)
90
Biozol Diagnostica Vertrieb GmbH galunisertib (ly2157299
Preparation and Characterization of the AuDNP-LY@Gel system. ( a ) Schematic representation of the functionalization procedure. The growth of AuNPs on the surface of the DNP is achieved by dispersing amino-modified DNPs in the HAuCl 4 solution and adding gelatin as a stabilizing agent. NaBH 4 is used as the reducing agent. Then, the small molecule <t>Galunisertib</t> is loaded into the system and the gelatin shell is performed by crosslinking of the polymer matrix. The scheme is not in scale and not intended to represent the full sample composition. ( b ) TEM investigations of the AuDNP (I), AuDNP-LY@Gel 0.125% (II) and AuDNP-LY@Gel 0.5% samples ( c ). Particle size analysis of AuNPs decorating the surface of the DNP fitted by a Gaussian curve. ( d ) Change in the size (black) and surface charge (blue) of the samples AuDNP-LY@Gel according to the different gelatin amounts in the outer shell. The vertical bars are representative of the standard deviation (SD) on a minimum of three independent measurements.
Galunisertib (Ly2157299, supplied by Biozol Diagnostica Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galunisertib (ly2157299/product/Biozol Diagnostica Vertrieb GmbH
Average 90 stars, based on 1 article reviews
galunisertib (ly2157299 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Future Drugs for HCC.

Journal: Journal of Clinical and Experimental Hepatology

Article Title: Hepatocellular Carcinoma: Etiology and Current and Future Drugs

doi: 10.1016/j.jceh.2019.01.004

Figure Lengend Snippet: Future Drugs for HCC.

Article Snippet: Galunisertib (LY2157299) , Eli Lilly , TGF-beta , II.

Techniques:

Different molecular targeted agents, and their combinations with other agents under clinical evaluation in HCC (as of December 2019) 1 .

Journal: Aging (Albany NY)

Article Title: New landscapes and horizons in hepatocellular carcinoma therapy

doi: 10.18632/aging.102777

Figure Lengend Snippet: Different molecular targeted agents, and their combinations with other agents under clinical evaluation in HCC (as of December 2019) 1 .

Article Snippet: , LY2157299 + Nivolumab (Opdivo®; Bristol-Myers Squibb Pharma EEIG) , II , active, not recruiting , NCT02423343.

Techniques: Transplantation Assay

Preparation and Characterization of the AuDNP-LY@Gel system. ( a ) Schematic representation of the functionalization procedure. The growth of AuNPs on the surface of the DNP is achieved by dispersing amino-modified DNPs in the HAuCl 4 solution and adding gelatin as a stabilizing agent. NaBH 4 is used as the reducing agent. Then, the small molecule Galunisertib is loaded into the system and the gelatin shell is performed by crosslinking of the polymer matrix. The scheme is not in scale and not intended to represent the full sample composition. ( b ) TEM investigations of the AuDNP (I), AuDNP-LY@Gel 0.125% (II) and AuDNP-LY@Gel 0.5% samples ( c ). Particle size analysis of AuNPs decorating the surface of the DNP fitted by a Gaussian curve. ( d ) Change in the size (black) and surface charge (blue) of the samples AuDNP-LY@Gel according to the different gelatin amounts in the outer shell. The vertical bars are representative of the standard deviation (SD) on a minimum of three independent measurements.

Journal: International Journal of Molecular Sciences

Article Title: Design of Gelatin-Capped Plasmonic-Diatomite Nanoparticles with Enhanced Galunisertib Loading Capacity for Drug Delivery Applications

doi: 10.3390/ijms221910755

Figure Lengend Snippet: Preparation and Characterization of the AuDNP-LY@Gel system. ( a ) Schematic representation of the functionalization procedure. The growth of AuNPs on the surface of the DNP is achieved by dispersing amino-modified DNPs in the HAuCl 4 solution and adding gelatin as a stabilizing agent. NaBH 4 is used as the reducing agent. Then, the small molecule Galunisertib is loaded into the system and the gelatin shell is performed by crosslinking of the polymer matrix. The scheme is not in scale and not intended to represent the full sample composition. ( b ) TEM investigations of the AuDNP (I), AuDNP-LY@Gel 0.125% (II) and AuDNP-LY@Gel 0.5% samples ( c ). Particle size analysis of AuNPs decorating the surface of the DNP fitted by a Gaussian curve. ( d ) Change in the size (black) and surface charge (blue) of the samples AuDNP-LY@Gel according to the different gelatin amounts in the outer shell. The vertical bars are representative of the standard deviation (SD) on a minimum of three independent measurements.

Article Snippet: Galunisertib (LY 2157299) was purchased from Axon Medchem (Groningen, NL).

Techniques: Modification, Polymer, Particle Size Analysis, Standard Deviation